New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
10:31 EDTEZPW, EXTR, NIHD, CROX, OREX, FL, SIAL, STLD, LCI, BBTHigh option volume stocks:
High option volume stocks: EZPW LCI STLD SIAL FL OREX CROX NIHD EXTR BBT
News For EZPW;LCI;STLD;SIAL;FL;OREX;CROX;NIHD;EXTR;BBT From The Last 14 Days
Check below for free stories on EZPW;LCI;STLD;SIAL;FL;OREX;CROX;NIHD;EXTR;BBT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 11, 2014
11:07 EDTOREXOptions with decreasing implied volatility
Subscribe for More Information
10:59 EDTOREXArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
10:49 EDTOREXHigh option volume stocks
Subscribe for More Information
10:29 EDTOREXOrexigen falls, levels to watch
Trading is volatile on very heavy volume nearing three times the daily average. At the current price of $5.41, next support is at $5.30, the low of the day, and then at $4.60 which is the 52-week low. Resistance is at $5.90, the prior session closing price.
10:00 EDTCROXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:55 EDTCROXCrocs retreats after Buckingham downgrades citing negative trends
Subscribe for More Information
09:22 EDTBBTBB&T sees 2015 organic growth 4%-6%
Subscribe for More Information
09:18 EDTCROXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: lululemon (LULU), up 15%... Sigma Designs (SIGM), up 7%. ALSO HIGHER: JDSU (JDSU), up 13.8% after announcing that it will separate into two publicly traded companies... Wet Seal (WTSL), up 4.5%, upgraded at B. Riley following Q2 earnings results... Gogo (GOGO), up 5% after announcing partnership with T-Mobile (TMUS)... Digital Ally (DGLY), up 8.4% after announcing plans to introduce "bullet camera" option at October police conference. DOWN AFTER EARNINGS: Restoration Hardware (RH), down 5%... Five Below (FIVE), down 5.6%. LOWER: Radio Shack (RSH), down 8% after reporting Q2 losses, stating that it may need to pursue bankruptcy... E2open (EOPN), down 29%, downgraded at Pacific Crest and Northland after the company announced preliminary Q2 earnings results... Twitter (TWTR), down 1% after announcing that it will offer $1.3B in convertible unsecured senior notes... Crocs (CROX), down 2.6% after downgraded at Buckingham... Macy's (M), down 1.3% after downgraded at Sterne Agee.
09:15 EDTBBTBB&T expects 2H14 average total loan growth to be 3%-5%
Subscribe for More Information
08:01 EDTOREXOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
07:43 EDTCROXCrocs downgraded to Neutral from Buy at Buckingham
Buckingham downgraded Crocs to Neutral based on slowing sales trends and incremental FX pressure. The firm does not believe a major sales inflection will occur until Spring 2016 at the earliest and notes Croc's profit improvement plan does not provide a time-frame for growth. Price target lowered to $13 from $20.
07:06 EDTOREXOrexigen's Contrave weight management tablets approved by FDA
Orexigen Therapeutics and Takeda Pharmaceuticals U.S.A. jointly announced that the FDA has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index indicating obese or overweight, in the presence of at least one weight-related comorbid condition. Takeda is planning to commercially launch Contrave in the fall.
06:49 EDTOREXFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).
September 10, 2014
18:27 EDTOREXOrexigen trading halted, pending news
Subscribe for More Information
13:36 EDTLCILannett receives FDA approval for oxycodone hydrochloride oral solution
Subscribe for More Information
September 9, 2014
15:27 EDTOREXOrexigen volatility elevated
Subscribe for More Information
12:46 EDTOREXNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
September 8, 2014
17:22 EDTOREXOrexigen, Takeda Pharmaceutical in services agreement
Orexigen disclosed in a regulatory filing that in preparation for the potential launch of NB32, Orexigen Therapeutics (OREX) and Takeda Pharmaceutical Company (TKPYY) entered into a Manufacturing Services Agreement, dated September 2, in accordance with the Collaboration Agreement between the company and Takeda, effective as of September 1, 2010, as amended by Amendment Number 1 to Collaboration Agreement effective as of September 26, 2013. Pursuant to the Agreement, among other things, the company will supply to Takeda, and Takeda will, subject to certain exceptions as set forth in the Agreement and Collaboration Agreement, exclusively purchase from the Company, all of Takeda’s requirements of NB32 for commercialization in the United States, Canada and Mexico during the term of the Collaboration Agreement. The Agreement will continue in full force and effect until the expiration or termination of the Collaboration Agreement.
11:29 EDTBBTBB&T to host investor day
Investor Day to be held in New York on September 11 at 9 am. Webcast Link
09:17 EDTBBTBB&T to acquire Bank of Kentucky for $363M
BB&T (BBT) and The Bank of Kentucky Financial Corporation (BKYF) announced the signing of a definitive agreement under which BB&T will acquire The Bank of Kentucky in a cash and stock transaction for total consideration valued at approximately $363M. The Bank of Kentucky, headquartered in Crestview Hills, Ky., has $1.9 billion in assets, $1.6 billion in deposits and 32 banking offices in Northern Kentucky and Cincinnati. Under the terms of the agreement, which was approved by the Board of Directors of each company, shareholders of The Bank of Kentucky will receive 1.0126 shares of BB&T common stock and $9.40 of cash for each share of The Bank of Kentucky common stock. Based on BB&T's 14-day average closing price of $37.13 as of September 4, 2014, shareholders of The Bank of Kentucky will receive $47.00 per share BB&T expects this acquisition to be accretive to earnings per share in the first full year and to exceed its IRR hurdle. The transaction is subject to customary closing conditions including regulatory approvals and approval of The Bank of Kentucky shareholders.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use